Kirsten Rackebrandt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kirsten Rackebrandt has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Huge
Core Facility Genomic, Medical Faculty of Muenster, University of Muenster, Albert-Schweitzer-Campus 1, D3, Domagstrasse 3, 48149 Muenster, Germany
1 shared publication - Eberhard von Hodenberg
Internal Medicine/Cardiology, Heart Center Lahr/Baden, 77933 Lahr, Germany
1 shared publication - Georg Haltern
11Heart Centre Wuppertal Helios-Kliniken, 42117 Wuppertal, Germany
1 shared publication - Hans-Peter Bestehorn
Heart Center Bad Krozingen, 79189 Bad Krozingen, Germany
1 shared publication - Mark Lankisch
Department of Cardiology, Witten/Herdecke University, HELIOS Klinikum Wuppertal, Germany
1 shared publication - Priska Binner
Institute for Heart and Circulation Research, University of Witten/Herdecke, 44227 Dortmund, Germany
1 shared publication
Latest Publications
- Open Access
- 8 October 2009
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 9 (1) , 48
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
Restenosis represents the major limiting factor for the long-term efficacy of percutaneous coronary intervention (PCI). Several genetic factors involved in the regulation of the vascular system have been described to play a role in the pathogenesis of restenosis. We investigated whether the EPHX2 K55R polymorphism, previously linked to significantly higher risk for coronary heart disease (CHD), was associated with the occurrence of restenosis after PCI. The association with incident CHD should have been confirmed and a potential correlation of the EPHX2 K55R variant to an increased risk of hypertension was analysed.
- 8 October 2009
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 9 (1) , 48
Open AccessVariation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
Restenosis represents the major limiting factor for the long-term efficacy of percutaneous coronary intervention (PCI). Several genetic factors involved in the regulation of the vascular system have been described to play a role in the pathogenesis of restenosis. We investigated whether the EPHX2 K55R polymorphism, previously linked to significantly higher risk for coronary heart disease (CHD), was associated with the occurrence of restenosis after PCI. The association with incident CHD should have been confirmed and a potential correlation of the EPHX2 K55R variant to an increased risk of hypertension was analysed.